Thymosin Alpha-1 vs Thymosin Beta-4 (TB-500): Two Unrelated Peptides

Why do they share the name thymosin?

In the search for thymic hormones, researchers prepared a standardized extract of calf thymus called thymosin fraction 5 and found that it was a mixture of small polypeptides¹. Several were purified and named from that mixture. Thymosin alpha-1 was sequenced in 1977 as a heat-stable, highly acidic peptide of 28 residues, and the authors proposed a naming scheme for the fraction 5 family². Thymosin beta-4 was sequenced in 1981 as a 43-residue peptide with an acetylated N-terminus³.

The shared name records where the peptides were found, not what they are. A review of the field concluded that none of the isolated fraction 5 peptides is really a thymic hormone, although each turned out to be biologically important in its own way¹. Thymosin alpha-1 derives from the protein prothymosin alpha⁴, while thymosin beta-4 belongs to the beta-thymosin family of actin-binding peptides⁵. Their sequences are unrelated, and research on one says little about the other.

What is thymosin alpha-1?

Thymosin alpha-1 (Tα1, thymalfasin) is the acetylated N-terminal segment of prothymosin alpha, with the sequence Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN. When prothymosin alpha was isolated from rat thymus, the researchers concluded that it was the native polypeptide from which Tα1 had been generated during preparation of fraction 5⁴. The clinical product is a synthetic version of the peptide⁶; the research material is described on our Thymosin Alpha-1 page.

Its research profile is immunological. In mouse and cell models, Tα1 activated dendritic cells through MyD88-dependent Toll-like receptor signaling, increased interleukin-12 production and protected transplanted mice from experimental aspergillosis⁷. Reviews describe a pleiotropic mechanism acting through Toll-like receptors on myeloid and plasmacytoid dendritic cells, with effects on several immune-cell subsets⁸.

Tα1 also has a clinical record that is unusual among research peptides. A 2009 review reported approvals in more than 35 countries for hepatitis B and C and as an immune stimulant and adjuvant⁶. Results are not uniformly positive: a phase 3 trial of 1,106 adults with sepsis found no difference in 28-day mortality between Tα1 and placebo⁹.

What is thymosin beta-4?

Thymosin beta-4 (Tβ4) is a 43-residue peptide of roughly 5 kDa with an acetylated N-terminus³. Its main known function was identified in 1991, when a platelet peptide that binds monomeric actin (G-actin) one-to-one and blocks its polymerization turned out to be identical to Tβ4¹⁰. Beta-thymosins are now regarded as the main intracellular G-actin-sequestering peptides in most vertebrate cells; Tβ4 is unstructured on its own and folds when it binds actin. Some effects have also been attributed to oxidized Tβ4 or to Ac-SDKP, a tetrapeptide that may be generated from it⁵.

Research later turned to Tβ4 outside the cell. In a rat full-thickness wound model, Tβ4 increased re-epithelialization, collagen deposition and angiogenesis, and it stimulated keratinocyte migration in vitro¹¹. In mice after coronary artery ligation, Tβ4 formed a complex with PINCH and integrin-linked kinase, activated the survival kinase Akt and was associated with better cardiac function¹².

Human data are limited. A small phase 2 trial of Tβ4 eye drops in nine patients with severe dry eye reported improvements in signs and symptoms compared with vehicle¹³. Tβ4 is not an FDA-approved drug.

What is TB-500?

TB-500 is a product name from the veterinary and research-chemical market, not a scientific name for Tβ4. When anti-doping chemists analyzed a TB-500 product, they identified the N-terminally acetylated 17–23 fragment of human Tβ4, Ac-LKKTETQ, then synthesized it by solid-phase synthesis and proposed methods to detect it in plasma and urine¹⁴. A separate equine study described TB-500 as a veterinary preparation whose key ingredient is acetylated LKKTETQ, identified that segment as the region of Tβ4 responsible for actin binding, and developed a method to detect it and its metabolites in horses¹⁵.

That distinction matters when reading the evidence. Most published Tβ4 studies used the full 43-residue protein, so their findings do not automatically apply to a seven-residue fragment. The TB-500 sold by Peptides Only is a seven-residue peptide, and its product page lists the formula and molecular weight. TB-500 is not an approved drug, and the World Anti-Doping Agency's Prohibited List names thymosin-β4 and its derivatives, such as TB-500, as prohibited in sport. For how TB-500 compares with another repair-focused peptide, see BPC-157 vs TB-500.

Thymosin alpha-1 vs thymosin beta-4 vs TB-500 at a glance

The table summarizes the differences described above; sources are cited in the surrounding sections.

How the research questions differ

Because the two peptides act on different systems, they are studied with different tools. Tα1 research asks immunological questions: how dendritic cells mature, which Toll-like receptors and adaptor proteins are engaged, and which cytokines follow^7,8. Tβ4 research is rooted in cytoskeletal biology: actin binding, cell migration, angiogenesis and repair after injury^10,11,12.

The two are sometimes discussed together because each was once described as a thymic hormone^3,1 and both appear in the same supplier catalogs. The literature reviewed here does not describe a shared receptor or pathway, and a study design suited to one is rarely appropriate for the other.

Limitations of the evidence

• Thymosin alpha-1: much of the mechanistic data comes from mouse and cell models⁷; the clinical record is larger but mixed, and the largest placebo-controlled sepsis trial was neutral⁹.
• Thymosin beta-4: most repair findings come from rodent models^11,12, and the human data cited here are a nine-patient phase 2 eye-drop study¹³.
• TB-500: published work on the acetylated LKKTETQ fragment is mostly analytical chemistry aimed at detecting it^14,15; its biology cannot be inferred from studies of full-length Tβ4.
• Approvals and clinical trials concern pharmaceutical products. Research-grade material is a different thing, sold for research use only, and needs its own lot-by-lot verification.

Telling them apart in the lab

Because the three differ so much in size, a mass-spectrometry identity test separates them easily: Tα1 is about 3.1 kDa⁴ and Tβ4 about 5 kDa³, while the TB-500 fragment is under 1 kDa. Every Peptides Only lot ships with a lot-matched certificate of analysis from an independent lab, with HPLC purity and mass-spec identity, published in the COA library. Our guide to reading a peptide COA explains what to check.